Cargando…
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
OBJECTIVES: To describe the use of baricitinib and tofacitinib by Swedish RA patients and to compare their effectiveness with that of biologic DMARDs (bDMARDs). METHODS: RA patients who initiated baricitinib (n = 1420), tofacitinib (n = 316), abatacept (n = 1050), IL-6 inhibitors (IL-6is; n = 849),...
Autores principales: | Barbulescu, Andrei, Askling, Johan, Chatzidionysiou, Katerina, Forsblad-d’Elia, Helena, Kastbom, Alf, Lindström, Ulf, Turesson, Carl, Frisell, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536798/ https://www.ncbi.nlm.nih.gov/pubmed/35134119 http://dx.doi.org/10.1093/rheumatology/keac068 |
Ejemplares similares
-
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
por: Bower, Hannah, et al.
Publicado: (2021) -
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
por: Bower, Hannah, et al.
Publicado: (2021) -
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
por: Frisell, Thomas, et al.
Publicado: (2018) -
HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020) -
The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study
por: Exarchou, Sofia, et al.
Publicado: (2015)